Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Total Non-Current Liabilities (2016 - 2025)

Apyx Medical (APYX) has disclosed Total Non-Current Liabilities for 14 consecutive years, with $51.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities rose 2.81% year-over-year to $51.7 million, compared with a TTM value of $51.7 million through Dec 2025, up 2.81%, and an annual FY2025 reading of $51.7 million, up 2.81% over the prior year.
  • Total Non-Current Liabilities was $51.7 million for Q4 2025 at Apyx Medical, up from $51.0 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $52.1 million in Q4 2023 and bottomed at $10.8 million in Q1 2021.
  • Average Total Non-Current Liabilities over 5 years is $31.4 million, with a median of $25.6 million recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities decreased 5.12% in 2022, then soared 277.65% in 2023.
  • Year by year, Total Non-Current Liabilities stood at $14.5 million in 2021, then fell by 5.12% to $13.8 million in 2022, then skyrocketed by 277.65% to $52.1 million in 2023, then decreased by 3.59% to $50.2 million in 2024, then grew by 2.81% to $51.7 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for APYX at $51.7 million in Q4 2025, $51.0 million in Q3 2025, and $50.4 million in Q2 2025.